




SECTOR OVERVIEW

The IIR Pharma & Biotech Index increased 2.9% in the month of June, in line with the broader market with the ASX All Ordinaries Accumulation Index up 2.6%. Of the 141 stocks in the index, 43 stocks posted positive share price gains in the month of June.

IIR Pharma & Biotech Index¹



The top 10 contributed strongly to the increase in the index with the top 10 constituents up 10.7% for the month. Race Oncology Ltd (ASX: RAC) joined the top 10 this month with Anteotech Ltd (ASX: ADO) slipping out of the top 10. RAC's share price was up 424.3% over the 12-months to 30 June 2021.

Telix Pharmaceuticals (ASX: TLX) was the best performer of the top 10 with the share price increasing 35.3% in June as positive news regarding the product suite continued. TLX's share price is up 375.8% for the 12-months to 30 June 2021.

Mayne Pharma (ASX: MYX) continued its slide from the highs in April with Credit Suisse trimming their price target for the company. Starpharma (ASX: SPL) also had a tough month, falling 15.8% on reports that it had received correspondence from regulators concerning promotional claims for the VIRALEZE product in both the UK and Australia with SPL pausing sales in the UK as the issues are addressed.

Top 10 Constituents of IIR Pharma & Biotech Index at 30 June 2020

Company	ASX Code
Pro Medicus Limited	PME
Polynovo Limited	PNV
Nanosonics Limited	NAN
Imugene Limited	IMU
Telix Pharmaceuticals Limited	TLX
Clinuvel Pharmaceuticals Limited	CUV
Mesoblast Limited	MSB
Starpharma Holdings Limited	SPL
Mayne Pharma Group Limited	MYX
Race Oncology Ltd	RAC

PERFORMANCE OF 2020 AND 2021 IPOs

With the IPO of Lumos Diagnostics Holdings Limited (ASX: LDX) on 1 July 2021, we thought it was a good time to check in to see how the IPOs of 2020 and 2021 have performed.

There were 13 IPOs in the sector in 2020 and 2021, not including LDX. Doctor Care Anywhere (ASX: DOC) was the largest IPO with the company raising \$102m at an issue price of \$0.80 per share. After hitting highs of \$1.50 shortly after listing, the share price has been on the decline for most of 2021, trading at a price of \$0.82 per share at 30 June.

A number of the IPOs were small with 7 of the 13 IPOs raising \$10m or less.

2020 and 2021 IPOs

Company Name	ASX Code	Listing Date	Amount Raised (\$m)	Sector
Control Bionics Limited	CBL	4-Dec-20	15.0	Health Care Equipment
Doctor Care Anywhere Group PLC	DOC	3-Dec-20	102.0	Health Care Technology
Hexima Limited	HXL	30-Nov-20	3.3	Biotechnology
4Dmedical Limited	4DX	6-Aug-20	55.8	Health Care Technology
Aroa Biosurgery Limited	ARX	23-Jul-20	45.0	Biotechnology
Intelicare Holdings Limited	ICR	21-May-20	5.5	Health Care Technology
Atomo Diagnostics Limited	AT1	14-Apr-20	30.0	Health Care Equipment
Little Green Pharma Ltd	LGP	19-Feb-20	10.0	Pharmaceuticals
Nyrada Inc	NYR	14-Jan-20	8.5	Pharmaceuticals
Argenica Therapeutics Limited	AGN	9-Jun-21	7.0	Pharmaceuticals
Island Pharmaceuticals Limited	ILA	9-Apr-21	7.5	Pharmaceuticals
Singular Health Group Ltd	SHG	10-Feb-21	6.0	Health Care Technology
Chimeric Therapeutics Limited	CHM	15-Jan-21	35.0	Biotechnology

The IPOs have performed relatively well with 9 of the 13 companies trading above the offer price at 30 June 2021. The median share price increase above the offer price of 15.8%.

LGP has been the best performer since its listing in February 2021, with the share price increasing 95.6% from the IPO offer price. LGP produces and sells medicinal cannabis oil products domestically and overseas. The company seen continued revenue growth and importantly in 1H'FY20 reported a Net Profit. 4DX and SHG have also performed strongly, posting share price gains of 67.8% and 55.0%, respectively.

HXL has fallen the most from the offer price, with the share price declining 15.0%. HXL is a clinical stage biotech company developing pezadeftide as a potential new subscription topical treatment for onychomycosis (toenail fungal infections). With a

1. The IIR Pharma & Biotech Index is a market capitalisation weighted index and currently includes 141 stocks across the Pharmaceutical, Biotech, Health Care Suppliers, Health Care Equipment, Health Care Technology and Life Sciences GICs sectors. The index excludes the five largest companies in these sectors being ANN, COH, CSL, FPH and RMD.

market capitalisation of less than \$20m, the company is small in size and there has been limited liquidity to date.

AT1 has fallen 7.5% from the offer price and CBL has increased 15.8%, however from the market open price upon listing the share prices have declined 52.6% and 37.9%, respectively.

Share Price Performance from Offer Price	
ASX Code	Share Price Performance
CBL	15.8%
DOC	2.5%
HXL	-15.0%
4DX	67.8%
ARX	49.3%
ICR	-10.0%
AT1	-7.5%
LGP	95.6%
NYR	60.0%
AGN	0.0%
ILA	12.0%
SHG	55.0%
CHM	45.0%

Source: Iress, IIR

COMPANY NEWS

Below we look at stocks in the IIR Pharma & Biotech Index that made notable announcements during the month that were received well by the market. These include: Prescient Therapeutics Limited (ASX: PTX), Patrys Limited (ASX: PAB), Cogstate Ltd (ASX: CGS), Vectus Biosystems Limited (ASX: VBS) and Suda Pharmaceuticals Ltd (ASX: SUD).

Prescient Therapeutics Limited (ASX: PTX)

PTX was the best performing stock in the IIR Pharma & Biotech index in June, with the share price rising 145%. During the month, PTX announced the successful completion of the manufacturing and delivery of crucial components of the OmniCAR platform for PTX's in-house programs of next generation CAR-T therapies. A range of binders against a variety of cancer targets have been manufactured and all binders have incorporated SpyTag, which is required for covalent binding to immune cells in the OmniCAR system. PTX has also received delivery of lentiviral vectors that will be used to produce CAR-T cells expressing SpyCatcher. Together the SpyTagged binders and CAR-T cells expressing SpyCatcher form the basis of the modular OmniCAR platform.

The Company has subsequently demonstrated that OmniCAR's key components show minimal immunogenicity in silico. Immunogenicity testing evaluates the immune response against a new therapy which can adversely affect safety and efficacy. In CAR-T cell therapies, high levels of immunogenicity can adversely impact CAR-T cell expansion and persistence, which can impact the overall safety and clinical response of the treatment. The immunogenicity testing of OmniCAR's binding components demonstrated very low immunogenicity, de-risking the platform and triggering the next steps in development.

Patrys Limited (ASX: PAB)

PAB's share price increased 107.4% in June. A key driver of the share price appreciation was the announcement of a publication of preclinical data that demonstrates the ability of PAB's PAT-DX1

antibody to cross the blood-brain barrier (BBB) and inhibit the growth of primary and secondary brain cancers.

The Company has subsequently announced new data from non-clinical studies that have confirmed its full-sized IgG deoxymab antibody (PAT-DX3), is able to cross the BBB in an animal model of primary brain cancer. Previous studies have shown that PAT-DX1, a deoxymab antibody fragment, is able to cross the BBB in animal models, however this is the first time it has been shown that the full size deoxymab, PAT-DX3, is also able to cross the BBB. The Company intends to follow up on the discovery with studies to compare the effect of both PAT-DX3 and PAT-DX1 on tumour reduction and survival in a range of primary and secondary brain cancer models.

Cogstate Ltd (ASX: CGS)

CGS's share price jumped markedly in June after announcing Eisai Co Ltd and their development partner, Biogen Inc, received accelerated approval for aducanumab (to be marketed as Aduhelm) by the FDA, the first ever disease-modifying Alzheimer's therapeutic. The announcement is a positive for CGS as CGS entered an agreement with Eisai Co Ltd in October 2020, granting Eisai the rights to exclusively develop and distribute CGS digital cognitive assessment technologies in healthcare and other markets worldwide. Since executing the agreement the two companies have progressed commercial plans for launching digital brain health assessment solutions using CGS technologies. It is expected that such digital cognitive assessment will play an important role in supporting the type of large-scale cognitive assessment necessary in the launch of disease modifying therapies such as Aduhelm.

Following the approval of Aduhelm, in addition to the minimum contractual royalty payments over the first five commercial years of US\$10m, Eisai are now also contractually obliged to make the minimum royalty payments over the following five commercial years of US\$20m.

Vectus Biosystems Limited (ASX: VBS)

VBS's share price rose 48.4% in June driven by the announcement that the Company had received approval for a Phase I Human Trial to determine the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004. The trials will commence in Melbourne in July 2021.

VB0004 aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure.

Suda Pharmaceuticals Ltd (ASX: SUD)

SUD's share price performed strongly in June, increasing 39%. The share price was buoyed by the announcement that the Company has licensed a novel invariant Natural Killer T (iNKT) cell therapy platform. The iNKT cell platform can be used in conjunction with multiple chimeric antigen receptors (CARs) to target blood cancers.

iNKT cells are expected to be suitable for off-the-shelf dosing, with one healthy donor able to supply cells to treat many patients. The natural properties of iNKT cells are expected to reduce the complexity of delivering the cell therapy to cancer patients and help to reduce the costs of treatment.

SUD has raised \$3.65m in a share placement to fund the initial development of the platform.

WHO IS IIR?

Independent Investment Research, "IIR", is an independent investment research house based in Australia and the United States. IIR specialises in the analysis of high quality commissioned research for Brokers, Family Offices and Fund Managers. IIR distributes its research in Asia, United States and the Americas. IIR does not participate in any corporate or capital raising activity and therefore it does not have any inherent bias that may result from research that is linked to any corporate/ capital raising activity.

IIR was established in 2004 under Aegis Equities Research Group of companies to provide investment research to a select group of retail and wholesale clients. Since March 2010, IIR (the Aegis Equities business was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers listed and unlisted managed investments, listed companies, structured products, and IPOs.

IIR takes great pride in the quality and independence of our analysis, underpinned by high caliber staff and a transparent, proven and rigorous research methodology.

INDEPENDENCE OF RESEARCH ANALYSTS

Research analysts are not directly supervised by personnel from other areas of the Firm whose interests or functions may conflict with those of the research analysts. The evaluation and appraisal of research analysts for purposes of career advancement, remuneration and promotion is structured so that non-research personnel do not exert inappropriate influence over analysts.

Supervision and reporting lines: Analysts who publish research reports are supervised by, and report to, Research Management. Research analysts do not report to, and are not supervised by, any sales personnel nor do they have dealings with Sales personnel

Evaluation and remuneration: The remuneration of research analysts is determined on the basis of a number of factors, including quality, accuracy and value of research, productivity, experience, individual reputation, and evaluations by investor clients.

INDEPENDENCE – ACTIVITIES OF ANALYSTS

IIR restricts research analysts from performing roles that could prejudice, or appear to prejudice, the independence of their research.

Pitches: Research analysts are not permitted to participate in sales pitches for corporate mandates on behalf of a Broker and are not permitted to prepare or review materials for those pitches. Pitch materials by investor clients may not contain the promise of research coverage by IIR.

No promotion of issuers' transactions: Research analysts may not be involved in promotional or marketing activities of an issuer of a relevant investment that would reasonably be construed as representing the issuer. For this reason, analysts are not permitted to attend "road show" presentations by issuers that are corporate clients of the Firm relating to offerings of securities or any other investment banking transaction from that our clients may undertake from time to time. Analysts may, however, observe road shows remotely, without asking questions, by video link or telephone in order to help ensure that they have access to the same information as their investor clients.

Widely-attended conferences: Analysts are permitted to attend and speak at widely-attended conferences at which our firm has been invited to present our views. These widely-attended conferences may include investor presentations by corporate clients of the Firm.

Other permitted activities: Analysts may be consulted by Firm sales personnel on matters such as market and industry trends, conditions and developments and the structuring, pricing and expected market reception of securities offerings or other market operations. Analysts may also carry out preliminary due diligence and vetting of issuers that may be prospective research clients of ours.

INDUCEMENTS AND INAPPROPRIATE INFLUENCES

IIR prohibits research analysts from soliciting or receiving any inducement in respect of their publication of research and restricts certain communications between research analysts and personnel from other business areas within the Firm including management, which might be perceived to result in inappropriate influence on analysts' views.

Remuneration and other benefits: IIR procedures prohibit analysts from accepting any remuneration or other benefit from an issuer or any other party in respect of the publication of research and from offering or accepting any inducement (including the selective disclosure by an issuer of material information not generally available) for the publication of favourable research. These restrictions do not preclude the acceptance of reasonable hospitality in accordance with the Firm's general policies on entertainment, gifts and corporate hospitality.

DISCLAIMER

This publication has been prepared by Independent Investment Research (Aust) Pty Limited trading as Independent Investment Research ("IIR") (ABN 11 152 172 079), an corporate authorised representative of Australian Financial Services Licensee (AFSL no. 410381. IIR has been commissioned to prepare this independent research report (the "Report") and will receive fees for its preparation. Each company specified in the Report (the "Participants") has provided IIR with information about its current activities. While the information contained in this publication has been prepared with all reasonable care from sources that IIR believes are reliable, no responsibility or liability is accepted by IIR for any errors, omissions or misstatements however caused. In the event that updated or additional information is issued by the "Participants", subsequent to this publication, IIR is under no obligation to provide further research unless commissioned to do so. Any opinions, forecasts or recommendations reflects the judgment and assumptions of IIR as at the date of publication and may change without notice. IIR and each Participant in the Report, their officers, agents and employees exclude all liability whatsoever, in negligence or otherwise, for any loss or damage relating to this document to the full extent permitted by law. This publication is not and should not be construed as, an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Any opinion contained in the Report is unsolicited general information only. Neither IIR nor the Participants are aware that any recipient intends to rely on this Report or of the manner in which a recipient intends to use it. In preparing our information, it is not possible to take into consideration the investment objectives, financial situation or particular needs of any individual recipient. Investors should obtain individual financial advice from their investment advisor to determine whether opinions or recommendations (if any) contained in this publication are appropriate to their investment objectives, financial situation or particular needs before acting on such opinions or recommendations. This report is intended for the residents of Australia. It is not intended for any person(s) who is resident of any other country. This document does not constitute an offer of services in jurisdictions where IIR or its affiliates do not have the necessary licenses. IIR and/or the Participant, their officers, employees or its related bodies corporate may, from time to time hold positions in any securities included in this Report and may buy or sell such securities or engage in other transactions involving such securities. IIR and the Participant, their directors and associates declare that from time to time they may hold interests in and/or earn brokerage, fees or other benefits from the securities mentioned in this publication.

IIR, its officers, employees and its related bodies corporate have not and will not receive, whether directly or indirectly, any commission, fee, benefit or advantage, whether pecuniary or otherwise in connection with making any statements and/or recommendation (if any), contained in this Report. IIR discloses that from time to time it or its officers, employees and related bodies corporate may have an interest in the securities, directly or indirectly, which are the subject of these statements and/or recommendations (if any) and may buy or sell securities in the companies mentioned in this publication; may affect transactions which may not be consistent with the statements and/or recommendations (if any) in this publication; may have directorships in the companies mentioned in this publication; and/or may perform paid services for the companies that are the subject of such statements and/or recommendations (if any).

However, under no circumstances has IIR been influenced, either directly or indirectly, in making any statements and/or recommendations (if any) contained in this Report. The information contained in this publication must be read in conjunction with the Legal Notice that can be located at <http://www.independentresearch.com.au/Public/Disclaimer.aspx>.